Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company’s web site at www.molecularinsight.com.
- 17 years ago
QualityStocks
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13
HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to…
-
QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Aligns with Sustainable Football Investment Trends Highlighted by WSJ
Brera Holdings (NASDAQ: BREA) reaffirmed its commitment to a sustainable, community-focused multi-club ownership model, drawing parallels…
-
QualityStocksNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) Successfully Road-Tests Thermoelectric Generator Radiator
First Tellurium (CSE: FTEL) (OTCQB: FSTTF) announced that its majority-owned subsidiary, PyroDelta Energy, has completed over…